ECG Low Ejection Fraction Detection and Guiding in AI Navigated Treatment Era

Launched by NATIONAL DEFENSE MEDICAL CENTER, TAIWAN · May 5, 2025

Keywords

ClinConnect Summary

The ELEGANT trial in Taiwan is testing whether an AI-assisted ECG screen can better identify people with early trouble in how the heart’s left ventricle pumps (a low ejection fraction) before symptoms appear, and whether this helps improve diagnosis and care compared with usual practice. Eligible adults are 60–85 years old, have had at least one standard ECG, do not have a history of heart failure or severely reduced heart pumping function, and have not had a heart ultrasound (echocardiogram) recently. If you join, you’ll be randomly assigned to one of two groups: AI-ECG guided diagnosis or standard clinical care.

In the AI-ECG group, everyone gets the AI screen; those at medium to high risk for left-ventricular dysfunction are advised to have an echocardiogram to confirm the diagnosis and guide treatment. In the standard-care group, diagnosis and management follow usual clinical practice, without automatic echo referrals based on the AI results. Researchers will look within 90 days at how often mild to significant dysfunction is detected, how many have severe dysfunction, how many heart-failure events occur, and how many receive an echocardiogram. The study is conducted at Tri-Service General Hospital, National Defense Medical Center in Taipei, aims to enroll about 13,350 people, and also evaluates cost-effectiveness and whether earlier detection reduces worsening heart failure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Outpatients with at least one 12-lead ECG
• • Age between 60-85 years
• Exclusion Criteria:
• • Documented echocardiography within the previous 6 months
• • Known severe LV dysfunction (LVEF \<40%)
• • Known heart failure history
• • Scheduled echocardiography exam